Veru, Inc. (VERU) Reports First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy
Tweet Send to a Friend
Veru Inc. (NASDAQ: VERU) today announced the enrollment of the first patient in its Phase 2 study of zuclomiphene citrate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
